Bladder Cancer And Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
Immune checkpoint inhibitors have greatly altered the treatment landscape for urothelial carcinoma. Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now approved for earlier treatment lines. The approval of Bavencio (Merck KGaA / Pfizer) as maintenance therapy for first-line locally advanced or metastatic urothelial carcinoma highlights the expanded use of immune checkpoint inhibitors in all lines of therapy. The regulatory approval of the antibody-drug conjugates Padcev (Seagen / Astellas) and Trodelvy (Gilead) has diversified the treatment paradigm for advanced and metastatic disease. Several new therapies and combinations anticipated to be approved by 2031 will only intensify the competition in this market.
QUESTIONS ANSWERED
- What are the sizes of the clinically and commercially relevant drug-treatable bladder cancer and upper tract urothelial carcinoma populations, and how will drug-treatment rates change over time?
- How is bladder cancer and UTUC currently treated? what are key differences in treatment between the two subtypes? What are the key advantages and disadvantages of existing drugs? What is the expected market impact of recent approvals?
- Which of the emerging therapies are viewed as most promising, and what sales / uptake could they secure in the bladder cancer and UTUC market?
- What are the key market drivers and constraints, and how will the market evolve over the 10-year forecast period?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Bladder Cancer And Upper Tract Urothelial Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Bladder Cancer and UTUC - Key Findings
- Key updates
- Q4 2022
- October 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- November 2021
- October 2021
- Q4 2022
- Market outlook
- Key findings
- Market share of drug classes for bladder cancer and UTUC: 2021
- Market share of drug classes for bladder cancer and UTUC: 2031
- Drug-treatable population share and major-market sales share in bladder cancer and UTUC: 2021
- Drug-treatable population share and major-market sales share in bladder cancer and UTUC: 2031
- Population positioning of therapies in bladder cancer and UTUC: United States
- Population positioning of therapies in bladder cancer and UTUC: Europe
- Population positioning of therapies in bladder cancer and UTUC: Japan
- Bladder cancer and UTUC SWOT analysis
- Market drivers and constraints
- What factors are driving the market for bladder cancer and UTUC?
- What factors are constraining the market for bladder cancer and UTUC?
- Major market sales of key therapies (excluding immune checkpoint inhibitors) in the bladder cancer and UTUC market: 2021-2031
- Major market sales of immune checkpoint inhibitors in the bladder cancer market and UTUC: 2021-2031
- Segment-specific trends
- Patient-share dynamics for key treatments for non-muscle-invasive bladder cancer in the United States: 2021-2031
- Patient-share dynamics for key treatments for non-muscle-invasive UTUC in the United States: 2021-2031
- Patient share dynamics for key treatments for non-muscle-invasive bladder cancer in Europe: 2021-2031
- Patient-share dynamics of key treatments for localized and resectable locally advanced muscle-invasive bladder cancer in the major markets: 2021-2031
- Patient-share dynamics of key treatments for localized and resectable locally advanced muscle-invasive UTUC in the major markets: 2021-2031
- Patient-share dynamics of key treatments in first-line unresectable locally advanced or metastatic bladder cancer and UTUC in the United States: 2021-2031
- Patient-share dynamics of key treatments for first-line unresectable locally advanced or metastatic bladder cancer and UTUC in Europe: 2021-2031
- Patient-share dynamics of key treatments for first-line unresectable locally advanced or metastatic bladder cancer and UTUC in Japan: 2021-2031
- Patient-share dynamics of key treatments for second-line metastatic bladder cancer and UTUC in the major markets: 2021-2031
- Patient-share dynamics of key treatments for third-line metastatic bladder cancer and UTUC in the major markets: 2021-2031
- Key findings
- Forecast
- Market forecast downloads
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Disease pathophysiology
- Anatomy of the urinary system
- Bladder cancer and upper tract urothelial carcinoma pathology
- Staging and classification
- Definitions of the TNM staging system for bladder cancer and UTUC
- AJCC / UICC TNM staging classification system for bladder cancer and UTUC
- Key pathways and drug targets
- Key pathways and drug targets for bladder cancer and upper tract urothelial carcinoma
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods bladder cancer
- Sources used for diagnosed incidence of bladder cancer
- Diagnosed incident cases of bladder cancer: 2021-2031
- Methods upper tract urothelial carcinoma
- Diagnosed incident cases of upper tract urothelial carcinoma: 2021-2031
- Disease definition
- Methods bladder cancer
- Sources used for stage distribution of bladder cancer
- Methods and sources used for upper tract urothelial carcinoma
- Diagnosed incident cases of bladder cancer by stage: 2021-2031
- Diagnosed incident cases of bladder cancer by muscle-invasiveness at diagnosis: 2021-2031
- Diagnosed incident cases of upper tract urothelial carcinoma by stage: 2021-2031
- Definition
- Methods
- Sources used for locally recurrent incident cases of bladder cancer and upper tract urothelial carcinoma
- Locally recurrent incident cases of bladder cancer: 2021-2031
- Locally recurrent incident cases of upper tract urothelial carcinoma: 2021-2031
- Definition
- Methods
- Sources used for intravesical recurrent incident cases of upper tract urothelial carcinoma
- Intravesical recurrent incident cases of upper tract urothelial carcinoma: 2021-2031
- Definition
- Methods
- Sources used for metastatic recurrent incident cases of bladder cancer and upper tract urothelial carcinoma
- Metastatic recurrent incident cases of bladder cancer: 2021-2031
- Metastatic recurrent incident cases of upper tract urothelial carcinoma: 2021-2031
- Bladder cancer and upper tract urothelial carcinoma patient flow
- Sources used for drug-treatable populations of bladder cancer and UTUC
- Drug-treatable cases of bladder cancer and UTUC: 2021-2031
- Drug-treated cases of bladder cancer and UTUC: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for bladder cancer and UTUC
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for bladder cancer and UTUC
- Current treatments used for bladder cancer and UTUC
- Market events impacting the use of key current therapies in bladder cancer and UTUC
- Key results from select clinical trials investigating Tecentriq for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of bladder cancer and UTUC
- Expert insight: Tecentriq
- Key results from select clinical trials investigating Opdivo for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of bladder cancer and UTUC
- Expert insight: Opdivo
- Key results from select clinical trials investigating Keytruda for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of bladder cancer and UTUC
- Expert insight: Keytruda
- Key results from select clinical trials investigating Bavencio for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Bavencio
- Key ongoing clinical trials of Bavencio in the treatment of bladder cancer and UTUC
- Expert insight: Bavencio
- Balversa
- Key results from select clinical trials investigating Balversa for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Balversa
- Key ongoing clinical trials of Balversa in the treatment of bladder cancer and UTUC
- Expert insight: Balversa
- Key results from select clinical trials investigating Padcev for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Padcev
- Key ongoing clinical trials of Padcev in the treatment of bladder cancer and UTUC
- Expert insight: Padcev
- Trodelvy
- Key results from select clinical trials investigating Trodelvy for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Trodelvy
- Key ongoing clinical trials of Trodelvy in the treatment of bladder cancer and UTUC
- Expert insight: Trodelvy
- Jelmyto
- Key results from select clinical trials investigating Jelmyto for the treatment of bladder cancer and UTUC
- Ongoing clinical development of Jelmyto
- Key ongoing clinical trials of Jelmyto in the treatment of bladder cancer and UTUC
- Expert insight: Jelmyto
- Medical practice
- Non-muscle-invasive bladder cancer and UTUC
- Localized and resectable locally advanced bladder cancer and UTUC
- First-line unresectable locally advanced or metastatic bladder cancer and UTUC
- Second- and third-line metastatic bladder cancer and UTUC
- Patient characteristics influencing drug selection in bladder cancer and UTUC
- Region-specific treatment practices
- Treatment decision tree for bladder cancer and UTUC: United States
- Treatment decision tree for bladder cancer and UTUC: Europe
- Treatment decision tree for bladder cancer and UTUC: Japan
- Key findings
- Unmet need overview
- Attainment of unmet needs
- Current and future attainment of unmet needs in bladder cancer and UTUC
- Top unmet bladder cancer and upper tract urothelial carcinoma: current and future attainment
- Expert insights: unmet need in bladder cancer and upper tract urothelial carcinoma
- Attainment of unmet needs
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for bladder cancer and UTUC
- Estimated market authorization dates of key emerging therapies for the treatment of bladder cancer and UTUC
- Key results from select clinical trials investigating sasanlimab for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for sasanlimab
- Key ongoing clinical trials of sasanlimab in the treatment of bladder cancer and UTUC
- Expert insight: sasanlimab
- Expectations for market authorization and sales opportunity of sasanlimab in bladder cancer and UTUC
- Key results from select clinical trials investigating cetrelimab for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for cetrelimab
- Key ongoing clinical trials of cetrelimab in the treatment of bladder cancer and UTUC
- Expert insight: Cetrelimab
- Expectations for market authorization and sales opportunity of cetrelimab in bladder cancer and UTUC
- Key results from select clinical trials investigating Imfinzi for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for Imfinzi
- Key ongoing clinical trials of Imfinzi in the treatment of bladder cancer and UTUC
- Expert insight: Imfinzi
- Expectations for market authorization and sales opportunity of Imfinzi in bladder cancer and UTUC
- Key results from select clinical trials investigating Instiladrin for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for Instiladrin
- Key ongoing clinical trials of Instiladrin in the treatment of bladder cancer and UTUC
- Expert insight: Instiladrin
- Expectations for market authorization and sales opportunity of Instiladrin in bladder cancer and UTUC
- Key results from select clinical trials investigating CG0070 in bladder cancer and UTUC
- Analysis of the clinical development program for CG0070
- Key ongoing clinical trials of CG0070 in the treatment of bladder cancer and UTUC
- Expert insight: CG0070
- Expectations for market authorization and sales opportunity of CG0070 in bladder cancer and UTUC
- Key results from select clinical trials investigating VesAnktiva for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for VesAnktiva
- Key ongoing clinical trials of VesAnktiva in bladder cancer and UTUC
- Expectations for market authorization and sales opportunity of VesAnktiva in bladder cancer and UTUC
- Key results from select clinical trials investigating TAR-200 for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for TAR-200
- Key ongoing clinical trials of TAR-200 in the treatment of bladder cancer and UTUC
- Expert insight: TAR-200
- Expectations for market authorization and sales opportunity of TAR-200 in bladder cancer and UTUC
- Key results from select clinical trials investigating UGN-102 for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for UGN-102
- Key ongoing clinical trials of UGN-102 in the treatment of bladder cancer and UTUC
- Expert insight: UGN-102
- Expectations for market authorization and sales opportunity of UGN-102 in bladder cancer and UTUC
- Key results from select clinical trials investigating truseltiq for the treatment of bladder cancer and UTUC
- Analysis of the clinical development program for Truseltiq
- Key ongoing clinical trials of Truseltiq in the treatment of Bladder cancer and UTUC
- Expert insight: Truseltiq
- Expectations for market authorization and sales opportunity of Truseltiq in Bladder cancer and UTUC
- Early-phase pipeline analysis
- Select compounds in early-phase development for bladder cancer and UTUC
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in bladder cancer and upper tract urothelial carcinoma: United States
- General reimbursement environment: United States
- Key market access considerations in bladder cancer and UTUC: EU5
- General reimbursement environment: EU5
- Key market access considerations in bladder cancer and UTUC: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Bladder cancer and UTUC bibliography
- Key findings
Liseth Parra, Ph.D., is an analyst on the Oncology team at Clarivate. She has extensive background in oncology research and market analysis. She completed a postdoctoral fellowship in oncology at Brigham and Women’s Hospital in Boston, along with commercial work as an oncology research analyst for Kantar Health and as an independent consultant. She also worked as a research fellow at the Novartis Institutes for BioMedical Research in Basel, Switzerland, and at the Fritz Lipmann Institute in Jena, Germany. Dr. Parra completed her doctorate in neurosciences at the University of California in San Diego.
Laura Vinuesa, D.V.M., M.Sc., is a senior business insights analyst on the Oncology team at Clarivate. She specializes in bladder cancer and head and neck cancers and in optimizing market access opportunities for new biomarker-targeted therapies in oncology. Previously, she was part of the Global Market Access Insights team, for whom she analyzed the healthcare systems and pharmaceutical markets of the EU5 and focused on evolving HTA demands, P&R processes, and stringent cost-containment strategies. She obtained her doctorate in veterinary medicine from Complutense University in Madrid and a master’s degree in clinical research and pharmaceutical medicine from EPHOS Business School in Madrid.